Lanza F L, Fakouhi D, Rubin A, Davis R E, Rack M F, Nissen C, Geis S
Baylor College of Medicine, Section of Gastroenterology, Houston, Texas.
Am J Gastroenterol. 1989 Jun;84(6):633-6.
Ibuprofen, a commonly proscribed nonsteroidal anti-inflammatory drug that is also available in many countries, including the United States, without a prescription, is known to cause hemorrhage and erosion of the gastroduodenal mucosa. This study was conducted to compare the efficacy of 200, 100, and 50 micrograms of misoprostol and placebo administered qid for 6 days, with a final dose on the morning of the 7th day, in the prevention of gastric and duodenal lesions induced by the concurrent administration of 800 mg of ibuprofen qid. A total of 120 healthy subjects with endoscopically normal gastric and duodenal mucosae were enrolled in the study. The endoscopic examination was repeated 2 h after the final dose on day 7, and the mucosae were graded on a 0 to 4+ scale. In the stomach, all three misoprostol groups were significantly more protective than placebo and did not differ significantly from each other. In the duodenum, the endoscopic scores of the 200- and 100-micrograms misoprostol groups, but not the 50-micrograms group differed significantly from placebo. The 200- and 100-microgram groups did not differ significantly from each other, but both differed from the 50-micrograms group for duodenal mucosal injury. Subjective symptoms thought to be primarily attributable to the NSAID (e.g., pain, indigestion/heartburn and nausea) were recorded by each subject in a diary. Subjects in the 200-micrograms misoprostol group attained the greatest degree of mucosal protection and had a significantly higher incidence of indigestion/heartburn and abdominal pain than the placebo group. One can conclude that misoprostol in both antisecretory (200- and 100-micrograms) and non-antisecretory (50-micrograms) doses protects the gastric mucosa from injury from high anti-inflammatory doses of ibuprofen (3200 mg/day). Only the antisecretory doses (100 and 200 micrograms qid) were effective in the duodenum, suggesting that acid suppression is necessary for mucosal protection to occur in the duodenum.
布洛芬是一种常用的非甾体抗炎药,在包括美国在内的许多国家无需处方即可获得,已知它会导致胃十二指肠黏膜出血和糜烂。本研究旨在比较每日四次、连续6天服用200微克、100微克和50微克米索前列醇及安慰剂,并在第7天早晨服用最后一剂,在预防因每日四次服用800毫克布洛芬同时给药所致胃十二指肠病变方面的疗效。共有120名胃十二指肠黏膜内镜检查正常的健康受试者参与了该研究。在第7天最后一剂服药后2小时重复进行内镜检查,并对黏膜进行0至4 +级评分。在胃中,所有三个米索前列醇组的保护作用均明显优于安慰剂组,且彼此之间无显著差异。在十二指肠中,200微克和100微克米索前列醇组的内镜评分与安慰剂组有显著差异,但50微克组无差异。200微克和100微克组彼此之间无显著差异,但在十二指肠黏膜损伤方面均与50微克组不同。每位受试者在日记中记录了被认为主要归因于非甾体抗炎药的主观症状(如疼痛、消化不良/烧心和恶心)。200微克米索前列醇组的受试者获得了最大程度的黏膜保护,且消化不良/烧心和腹痛的发生率明显高于安慰剂组。可以得出结论,抗分泌剂量(200微克和100微克)和非抗分泌剂量(50微克)的米索前列醇均可保护胃黏膜免受高抗炎剂量布洛芬(3200毫克/天)的损伤。只有抗分泌剂量(每日四次100和200微克)对十二指肠有效,这表明抑制胃酸分泌对于十二指肠黏膜保护的发生是必要的。